AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$GLUE

Warmuth Markus sold $106K of GLUE

Warmuth Markus (President & CEO) sold 5,466 shares of Monte Rosa Therapeutics, Inc. (GLUE) at an average of $19.44 ($19.41–$19.73, $0.11M total) across 2 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Warmuth Markus
Published Jun 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GLUE
Bearish
high confidence
Mentioned
$GLUE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUEBearishLow
01

Why it matters

The disclosure is a primary source filing; the transaction size is modest, likely causing limited price movement.

02

Market read

First‑report insider sale; modest impact on GLUE's share price.

03

What to watch

Insider retains a large stake, suggesting continued confidence despite the sale.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

Monte Rosa Therapeutics (GLUE) filed a Form 4 reporting a $106K insider sale by its CEO under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$GLUEBearishHigh confidence
Context

President & CEO Warmuth Markus sold 5,466 shares for $106K via a 10b5‑1 plan, reducing his stake to 594,538 shares.

Expected impact

likely modest downward pressure as market prices in insider sale

Evidence & confidence

Form 4 filing is the first public disclosure of the sale; the amount is small relative to float, so impact is limited.

Market effects

Sector

No broader sector impact; typical insider sale in biotech.

Regional

U.S. market only.

Global

Limited to Monte Rosa investors.

Counterpoint

What could challenge this read

The sale may be routine and not indicative of future performance; investors could view it as neutral.

Key entities

  • company
    Monte Rosa Therapeutics, Inc.

    Biotech company listed on Nasdaq under ticker GLUE.

  • person
    Warmuth Markus

    President & CEO of Monte Rosa Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GLUE insider trading history →

Related articles

SEP 13
$NVSMed

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Monte Rosa Therapeutics (GLUE) received a $50M milestone payment from Novartis (NVS) for the first patient dosed in a Phase 2 trial of MRT-6160 for Sjögren’s disease. The deal could be worth up to $2.1B. Monte Rosa reported Q2 2026 revenue of $9M, up from $23.2M a year earlier, with a net loss of $43.4M. The company has multiple clinical trials ongoing and $626M in cash.

insidermonkey.com3 min
SEP 8
$GLUEMedAI 8/10

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Therapeutics (GLUE) announced that Novartis has initiated a Phase 2 study for MRT-6160 (DDY391) in Sjögren's disease patients. Monte Rosa will receive a $50 million milestone payment. The study is part of a global license agreement where Novartis has exclusive rights to develop and commercialize VAV1 MGDs, with Monte Rosa eligible for up to $2.1 billion in milestones.

finanznachrichten.de2 min
SEP 8
$NVSMedAI 8/10

Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease

Novartis (NVS) has begun a Phase 2 study of MRT-6160 for Sjögren’s disease. Monte Rosa Therapeutics (GLUE) will receive a $50M milestone payment. The study aims to evaluate efficacy, safety, and tolerability of the treatment. MRT-6160 is a VAV1-directed molecular glue degrader. Novartis holds exclusive rights under a licensing agreement, with Monte Rosa eligible for up to $2.1B in milestones.

investing.com2 min